The primary objective of the Pathology Core for this P01 is to facilitate the discovery and validation of novel targets and therapies for melanoma. To test the therapeutic efficacy of targeted therapies, it is essential to conduct well-planned research using state-of-the art preclinical models;these include patient-derived xenografts (PDXs), transgenic Tyr:creERT2, BRAF[CA/+], [ca/+], PTEN[lox/lox] melanoma mice, and syngeneic models using melanoma cell lines from the mice. As over 1000 patients with melanoma are seen and treated at University of Pennsylvania Health system per year, the Pathology Core is well equipped to provide fresh melanoma tissues to the Cell Biology Core to generate PDXs. Standardized procedures for procurement, processing, storage, quality control, histopathologic evaluation and distribution of samples will ensure optimal utilization and distribution of limited tissue samples to P01 projects. In addition to human samples, the pathology core will serve as a central repository for all mouse tissue generated by this P. The Pathology Core will provide technical support for developing and performing tissue-based assays and the core pathologist will provide expert pathological assistance in the interpretation of histological and immunostaining data. Centralized tissue repository, tissue processing, result acquisition and data interpretation will enable more collaboration across projects and allow new paths of research to emerge. The Core is led by a senior dermatopathologist with extensive experience in translational and laboratory investigation. The Pathology Core will interact with other P01 Cores and other core facilities at Penn and Wistar to support P01 projects. This coordination will allow the P01 investigators to most efficiently perform tissue-based research to find new therapeutic targets as well as to evaluate new combination therapies. In addition to tailoring services to the needs of each project, the central coordination and analysis of tissue will be time- and cost-effective.

Public Health Relevance

Melanoma is the most aggressive form of skin cancer and the incidence of melanoma continues to rise worldwide. Current melanoma therapies are either ineffective or they elicit short-lived responses due to the rapid development of treatment resistance. The Pathology Core will allow the P01 investigators to most efficiently perform tissue-based research to find new therapeutic targets as well as to evaluate new combination therapies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-2 (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wistar Institute
United States
Zip Code
Kaur, Amanpreet; Webster, Marie R; Marchbank, Katie et al. (2016) sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 532:250-4
Budina-Kolomets, Anna; Webster, Marie R; Leu, Julia I-Ju et al. (2016) HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Res 76:2720-30
Lu, Hezhe; Liu, Shujing; Zhang, Gao et al. (2016) Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Rep 15:2012-24
Amaravadi, Ravi; Kimmelman, Alec C; White, Eileen (2016) Recent insights into the function of autophagy in cancer. Genes Dev 30:1913-30
Krepler, Clemens; Xiao, Min; Samanta, Minu et al. (2016) Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma. Oncotarget :
Grasso, Michael; Estrada, Michelle A; Ventocilla, Christian et al. (2016) Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF(V600E) Conformation. ACS Chem Biol 11:2876-2888
Shannan, Batool; Chen, Quan; Watters, Andrea et al. (2016) Enhancing the evaluation of PI3K inhibitors through 3D melanoma models. Pigment Cell Melanoma Res 29:317-28
Jennis, Matthew; Kung, Che-Pei; Basu, Subhasree et al. (2016) An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev 30:918-30
Chatwichien, Jaruwan; Basu, Subhasree; Budina-Kolomets, Anna et al. (2016) PUMA-dependent apoptosis in NSCLC cancer cells by a dimeric β-carboline. Bioorg Med Chem Lett 26:4884-4887
Krepler, Clemens; Xiao, Min; Sproesser, Katrin et al. (2016) Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res 22:1592-602

Showing the most recent 10 out of 87 publications